Australia's InhaleRx gains on securing funding for depression therapy SRX-25

Nexalis Therapeutics

04/12/2025 24:49

** Shares of Australia's InhaleRx IRX.AX rise as much as 7.7% to A$0.027, posting their biggest intraday pct gain since November 20

** Medical device maker gets A$12.6 million ($8.32 million)in additional funding to support development of SRX-25, an oral fixed-dose combination therapy targeting treatment-resistant depression

** Stock has fallen 19.4% this year, including day's moves

($1 = 1.5145 Australian dollars)

(Reporting by Roshan Thomas in Bengaluru)

((Roshan.Thomas@thomsonreuters.com;))